Additionally, final 503B guidance released in January 2025 states that 503B facilities cannot compound using bulk drug substances while the FDA is deciding whether or not to place the ingredient on the bulk drug substance list
Wipe away excess with a soft cloth or tissue
The scenario where adding phentermine makes the strongest case is this: a patient on maximum tirzepatide dosing for at least 6 months, with a documented weight loss plateau lasting 8 or more weeks, who has optimized diet, exercise, sleep, and stress management, and whose provider has ruled out medical causes for the plateau (thyroid dysfunction, medication interactions, fluid retention)
That means the default pathway to market is the same gauntlet every pharmaceutical faces: preclinical studies, Investigational New Drug (IND) applications, phased clinical trials, and a New Drug Application (NDA) (or an Abbreviated New Drug Application (ANDA) for generics)
However, if youre struggling with mast cell activation syndrome (MCAS), your mast cells are over-producing histamines whether there is a trigger or not